Personalis, Inc. shares rise 1.03% premarket after announcing new data from AstraZeneca phase 3 clinical trial.

Personalis, Inc. rose 1.03% in premarket trading, with the company announcing new data from an AstraZeneca phase 3 clinical trial in lung cancer. The findings demonstrate that Personalis' highly sensitive molecular residual disease (MRD) test, NeXT Personal®, is a strong predictor of outcomes in patients with stage II-IIIb, EGFR-mutated non-small cell lung cancer (NSCLC) receiving neoadjuvant therapy. The findings will be presented at the IASLC 2025 World Conference on Lung Cancer.